Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05905965 | Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment | PHASE3 | RECRUITING | 200 | — | — | May 1, 2023 | Mar 31, 2026 | Aug 27, 2024 | 1 | Poland |
change in BMI between study arms
change in glycated hemoglobin plasma concentration between study arms
| Arm | Type | Description |
|---|---|---|
| Empagliflozin 20 mg | EXPERIMENTAL | Patients receiving empagliflozin 20 mg daily |
| Empagliflozin 10 mg | ACTIVE_COMPARATOR | Patients receiving empagliflozin 10 mg daily |
| Name | Type | Description |
|---|---|---|
| Empagliflozin 20 mg | DRUG | Patients receiving empagliflozin 20 mg daily - experimental arm |
| Empagliflozin 10 mg | DRUG | Patients receiving empagliflozin 10 mg daily - control arm |
Inclusion Criteria: * diagnosis of metabolic syndrome as follows: the presence of obesity (waist circumference ≥ 88 cm in women; ≥102 cm or body mass index (BMI) ≥30 kg/m2) and two of the three following criteria: 1. high blood pressure (systolic blood pressure - in-office measurement: ≥ 130 and...